Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity

2021 | journal article

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity​
Becker, M.; Strengert, M.; Junker, D.; Kaiser, P. D.; Kerrinnes, T.; Traenkle, B. & Dinter, H. et al.​ (2021) 
Nature Communications12(1).​ DOI: https://doi.org/10.1038/s41467-021-20973-3 

Documents & Media

document.pdf1.91 MBAdobe PDF

License

GRO License GRO License

Details

Authors
Becker, Matthias; Strengert, Monika; Junker, Daniel; Kaiser, Philipp D.; Kerrinnes, Tobias; Traenkle, Bjoern; Dinter, Heiko; Häring, Julia; Ghozzi, Stéphane; Zeck, Anne; Schneiderhan-Marra, Nicole
Abstract
Abstract The humoral immune response to SARS-CoV-2 is a benchmark for immunity and detailed analysis is required to understand the manifestation and progression of COVID-19, monitor seroconversion within the general population, and support vaccine development. The majority of currently available commercial serological assays only quantify the SARS-CoV-2 antibody response against individual antigens, limiting our understanding of the immune response. To overcome this, we have developed a multiplex immunoassay (MultiCoV-Ab) including spike and nucleocapsid proteins of SARS-CoV-2 and the endemic human coronaviruses. Compared to three broadly used commercial in vitro diagnostic tests, our MultiCoV-Ab achieves a higher sensitivity and specificity when analyzing a well-characterized sample set of SARS-CoV-2 infected and uninfected individuals. We find a high response against endemic coronaviruses in our sample set, but no consistent cross-reactive IgG response patterns against SARS-CoV-2. Here we show a robust, high-content-enabled, antigen-saving multiplex assay suited to both monitoring vaccination studies and facilitating epidemiologic screenings for humoral immunity towards pandemic and endemic coronaviruses.
Issue Date
2021
Journal
Nature Communications 
eISSN
2041-1723
Language
English
Sponsor
EC | Horizon 2020 Framework Programme https://doi.org/10.13039/100010661
Initiative and Networking Fund of the Helmholtz Association of German Research Centres - grant number SO-96

Reference

Citations


Social Media